This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kotloff, K. L. Articles by Fischetti, V. A. Search for Related Content PubMed PubMed Citation Articles by Kotloff, K. L. Articles by Fischetti, V. A.

Clinical and Microbiological Responses of Volunteers to Combined Intranasal and Oral Inoculation with a Streptococcus gordonii Carrier Strain Intended for Future Use as a Group A Streptococcus Vaccine

Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics,¹ Division of Geographic Medicine, Department of Medicine,² Center for Vaccine Development, School of Medicine, University of Maryland, Baltimore, Maryland,³ SIGA Technologies, Inc., Corvallis, Oregon,⁴ Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York⁵

Received 12 July 2004/ Returned for modification 29 September 2004/ Accepted 3 December 2004

Streptococcus gordonii shows promise as a live mucosal vaccine vector for immunization against respiratory pathogens. In preparation for clinical trials to evaluate S. gordonii engineered to express group A streptococcal M protein antigens, we characterized the responses of 150 healthy volunteers to combined nasal and oral inoculation with approximately 1.5 x 10⁹ CFU of SP204(1-1), an S. gordonii strain not bearing vaccine antigens. SP204(1-1) was selected for resistance to streptomycin and 5-fluoro-2-deoxyuridine to distinguish it from indigenous flora. In two antibiotic treatment studies, we performed serial culturing of nose, mouth, and saliva samples from 120 subjects treated with azithromycin beginning 5 days after inoculation to determine whether SP204(1-1) could be rapidly eliminated should safety concerns arise. A natural history study was performed to assess the time until spontaneous eradication in the remaining 30 subjects, who did not receive the antibiotic and who were monitored with repeated culturing for 14 weeks after inoculation. SP204(1-1) was generally well tolerated. Symptoms reported most often within 5 days of inoculation were nasal congestion (36%), headache (30%), and sore throat (19%). The strain was detected by culturing in 98% of subjects. A single dose of azithromycin eliminated colonization in 95% of subjects; all subjects receiving a 5-day course of an antibiotic showed clearance by day 11. Without the antibiotic, 82% of subjects showed spontaneous eradication of the implanted strain within 7 days, and all showed clearance by 35 days. The results of these clinical trials provide encouragement that the use of S. gordonii as a live mucosal vaccine vector is a feasible strategy.

Editor: J. N. Weiser

This article has been cited by other articles:

• Chan, K. G., Mayer, M., Davis, E. M., Halperin, S. A., Lin, T.-J., Lee, S. F. (2007). Role of D-Alanylation of Streptococcus gordonii Lipoteichoic Acid in Innate and Adaptive Immunity. Infect. Immun. 75: 3033-3042 [Abstract] [Full Text]  
• Bizzini, A., Majcherczyk, P., Beggah-Moller, S., Soldo, B., Entenza, J. M., Gaillard, M., Moreillon, P., Lazarevic, V. (2007). Effects of {alpha}-phosphoglucomutase deficiency on cell wall properties and fitness in Streptococcus gordonii. Microbiology 153: 490-498 [Abstract] [Full Text]  
• Ciabattini, A., Cuppone, A. M., Pulimeno, R., Iannelli, F., Pozzi, G., Medaglini, D. (2006). Stimulation of Human Monocytes with the Gram-Positive Vaccine Vector Streptococcus gordonii.. CVI 13: 1037-1043 [Abstract] [Full Text]  
• Medaglini, D., Ciabattini, A., Cuppone, A. M., Costa, C., Ricci, S., Costalonga, M., Pozzi, G. (2006). In Vivo Activation of Naive CD4+ T Cells in Nasal Mucosa-Associated Lymphoid Tissue following Intranasal Immunization with Recombinant Streptococcus gordonii.. Infect. Immun. 74: 2760-2766 [Abstract] [Full Text]